Gilead Sciences, Inc.
HealthcareNASDAQ:GILD · NASDAQ Global Select
-$0.73 today
Vol 2.66M · Avg 6.62M
Intrinsic Value
GILD Intrinsic Value
Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.
Intrinsic Value
System DCF · consensus of 4 models
Sign in to unlock intrinsic value
Free accounts get 5 valuations per week. Upgrade for more.
Monitor GILD
Get notified when the price moves into your range
Use alerts to turn the valuation into an action plan instead of checking the stock manually.
Price Alerts
Get notified when GILD drops below a target
Sign in to activate price alerts · unlock IV-based targets
Valuation History
Is GILD cheaper or more expensive than usual?
Review how the market has valued Gilead Sciences, Inc. over time before deciding whether today’s discount or premium is unusual.
Price History
Dividend-adjusted closing price
Change
+14.79%
Period High
$154.92
Period Low
$103.91
Latest
$125.28
Analyst Targets
See where analysts expect GILD to trade next
Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.
Wall Street Price Targets
1-year price history with analyst consensus target
Current
$125.28
Low Target
$122.00
Avg Target
$161.12
High Target
$180.00
Upside (Avg)
+28.61%
Alternatives to GILD
Compare Gilead Sciences, Inc. with similar companies
A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.
Competitors
Peer companies in the same sector
Merck & Co., Inc.
NYSE:MRK
$296.05B
Novo Nordisk A/S
NYSE:NVO
$196.75B
Amgen Inc.
NASDAQ:AMGN
$190.71B
Pfizer Inc.
NYSE:PFE
$149.18B
Danaher Corporation
NYSE:DHR
$127.48B
Stryker Corporation
NYSE:SYK
$120.34B
Bristol-Myers Squibb Company
NYSE:BMY
$116.57B
GSK plc
NYSE:GSK
$106.57B
Sanofi
NASDAQ:SNY
$106.47B
Boston Scientific Corporation
NYSE:BSX
$69.91B
Fundamental Analysis
Capture the investment case and test company quality
Write down the key idea, risks, and what would change your mind. Then review growth, profitability, returns, owner payouts, and insider activity.
My Notes
Journal entries for GILD
Sign in to keep notes
Track your buy/sell/hold decisions for every stock in your personal journal.
Quality Snapshot
Start with the numbers that compound value
Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | N/A | N/A | +93.7% | +62.0% |
Revenue | N/A | N/A | +49.8% | +31.1% |
Equity | +14.2% | +3.0% | +0.4% | +15.7% |
Cash | N/A | N/A | +92.4% | +28.2% |
ROIC | 18.7% | 7.9% | 7.0% | 12.8% |
Analysis
Latest growth is strongest in EPS at +62.0% and weakest in ROIC at 12.8%. Three-year average ROIC is 7.0%, which helps show whether that growth is being earned efficiently.
Growth Profile
Compare historical growth with forward expectations
Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +93.7% | +0.5% (15yr)3 analysts |
| Revenue | N/A | N/A | +49.8% | +1.0% (15yr)11 analysts |
| Net Income | N/A | N/A | +91.2% | -0.8% (15yr)11 analysts |
| EBIT | N/A | N/A | +76.9% | -5.2% (15yr)11 analysts |
Analysis
Recent growth has been strongest in EPS at +93.7% over three years. Forward estimates point to Revenue at +1.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Earnings Quality
Follow revenue through to net income
Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$29.7B of revenue converted into $9.2B of net income for the selected period. Gross margin is 79.3% and net margin is 30.9%, showing how much revenue survives after costs and taxes. EPS is $7.34, tying the income statement back to per-share earnings.
Capital Efficiency
Measure how well Gilead Sciences, Inc. turns capital into returns
Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.
Return Metrics
ROE, ROIC & ROA over time
ROE
37.6%
avg 32.5%
ROIC
21.5%
avg 14.4%
ROA
14.4%
avg 11.2%
Analysis
ROE is currently the strongest return metric at 37.6% versus its period average of 32.5%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Owner Returns
Review how cash comes back to shareholders
Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.
Shareholder Returns
Dividend, buyback & debt paydown yields
Dividend Yield (TTM)
2.60%
Buyback Yield (TTM)
1.04%
Debt Paydown (TTM)
1.80%
Total Yield (TTM)
5.43%
Analysis
Total TTM shareholder yield is 5.43% including 1.80% from debt paydown. The largest current contributor is dividends at 2.60%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.
Dividend Record
Check payout durability before counting on yield
A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.
Dividends
Dividend history, growth & yield
Yield
2.55%
Annual Div/Share
$3.19
Payout Ratio
43.8%
Frequency
Quarterly
Shareholder Yield
3.81%
Next Ex-Date
Jun 15, 2026
Next Payment
$0.82 · Jun 29, 2026
1Y Growth
+2.9%
3Y CAGR
+2.8%
5Y CAGR
+3.0%
Dividend Payments, Annual Total (TTM) & Yield
Analysis
The current indicated dividend yield is 2.55%, with TTM dividends of $3.19 per share. Three-year dividend growth is +2.8%, which helps show whether payouts are compounding or flattening. The payout ratio is 43.8%, so compare payout growth against earnings coverage. Payments are currently quarterly.
Company Overview
Understand how Gilead Sciences, Inc. makes money
Finish by grounding the numbers in the company profile, leadership, balance sheet, and free cash flow.
Key Information
Leadership
Put the business in management context
Company facts explain what Gilead Sciences, Inc. does; leadership context helps you judge who is responsible for capital allocation and execution.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel O'Day | Chairman & Chief Executive Officer | $8.70M | — | 61 | $626,346.00 | 0.05% |
Dietmar Berger | Chief Medical Officer | $5.92M | — | 57 | $46,928.00 | <0.01% |
Johanna Mercier | Chief Commercial & Corporate Affairs Officer | $3.44M | — | 56 | $128,575.00 | 0.01% |
Andrew D. Dickinson | Executive VP & CFO | $3.14M | — | 56 | $175,987.00 | 0.01% |
Linda Slanec Higgins | Senior Vice President of Research, Innovation & Portfolio | — | — | 64 | — | — |
Jacquie Ross | Senior Vice President of Treasury and Investor Relations | — | — | — | — | — |
Jyoti K. Mehra | Executive Vice President of Human Resources | — | — | 49 | — | — |
Stacey Y. Ma | Executive Vice President of Pharmaceutical Development & Manufacturing | — | — | 55 | — | — |
Bernard Fine | Vice President of Oncology & Franchise Head of Early Development | — | — | — | — | — |
Janet Dorling | Senior Vice President of Intercontinental Region & Global Patient Solutions | — | — | 51 | — | — |
Flavius Martin | Executive Vice President of Research | — | — | — | — | — |
Erin Burkhart | Senior VP, Controller & Chief Accounting Officer | — | — | 47 | $11,245.00 | <0.01% |
Keeley Wettan | Executive VP, General Counsel of Legal & Compliance and Secretary | — | — | 51 | $19,997.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
60
$76.78M
Net Sentiment
$76.78M
Net selling
Most Active
O'Day Daniel Patrick
23 transactions
1–10 of 60
Analysis
Insiders reported 0 buys worth $0.00 and 60 sells worth $76.78M over the last 12 months. That adds up to net selling of $76.78M. O'Day Daniel Patrick was the most active insider with 23 transactions.
Financial Position
Check what supports the company underneath the income statement
The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $7.6B |
| Short-term Investments | $2.2B |
| Receivables | $4.7B |
| Inventory | $1.9B |
| Other Current | $2.2B |
| Total Current Assets | $18.6B |
| PP&E (Net) | $5.6B |
| Goodwill | $8.3B |
| Intangible Assets | $16.4B |
| Long-term Investments | $1.7B |
| Tax Assets | $1.8B |
| Other Non-current | $3.9B |
| Total Non-current Assets | $37.6B |
| Total Assets | $56.3B |
Analysis
Selected assets total $56.3B for Latest. The largest visible component is Intangible Assets at $16.4B, about 29.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Cash Generation
Finish by testing whether profit turns into cash
Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Explore More
Continue the stock analysis
Jump to another research area for this company.